

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

INTERLEUKIN GENETICS INC

Form 8-K

November 04, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2005

-----  
Interleukin Genetics, Inc.  
-----

(Exact name of registrant as specified in its charter)

Delaware

000-23413

94-3123681

-----  
(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

135 Beaver Street Waltham, MA

02452

-----  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (781) 398-0700

-----  
(not applicable)

-----  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2005, Interleukin Genetics, Inc. issued a press release to report its consolidated financial results for the quarter ended September 30, 2005. A copy of the earnings press release is being furnished pursuant to this

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(c) The following exhibit is furnished with this report:

Exhibit No.	Description
-----	-----
99.1	Earnings Press Release dated November 4, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERLEUKIN GENETICS, INC.

Date: November 4, 2005

By: /s/ PHILIP R. REILY  
-----  
Philip R. Reilly  
Chief Executive Officer